Publications: Research Papers


Equity and Pandemic Preparedness: Navigating the 2024 Amendments to the International Health Regulations
Research Paper 206, 28 August 2024

By Nirmalya Syam

Negotiating Health and Autonomy: Data Exclusivity, Healthcare Policies and Access to Pharmaceutical Innovations
Research Paper 204, 24 July 2024

By Henrique Zeferino De Menezes, Julia Paranhos, Ricardo Lobato Torres, Luciana Correia Borges, Daniela De Santana Falcão and Gustavo Soares Felix Lima

The Vaccine Industry After the COVID-19 Pandemic: An International Perspective
Research Paper 203, 11 July 2024

By Felix Lobo
What Can Cambodia Learn from Thailand and India as It Prepares to Graduate from Least Developed Country Status?
Research Paper 198, 31 May 2024

By Brigitte Tenni, Deborah Gleeson, Joel Lexchin, Phin Sovath, and Chalermsak Kittitrakul
Compulsory Licensing as a Remedy Against Excessive Pricing of Life-Saving Medicines
Research Paper 197, 28 May 2024

By Behrang Kianzad
Licencias obligatorias para exportación: operacionalización en el orden jurídico argentino
Documento de Investigación 196, 19 de abril de 2024

Por Valentina Delich
Régimen de licencias obligatorias y uso público no comercial en Argentina
Documento de Investigación 195, 6 de marzo de 2024

Por Juan Ignacio Correa
Implementation of TRIPS Flexibilities and Injunctions: A Case Study of India
Research Paper 194, 15 February 2024

By Shirin Syed
Desafíos actuales y posibles escenarios futuros de la salud mundial
Documento de Investigación 193, 2 de Febrero de 2024

By Germán Velásquez
Pautas para el examen de patentes sobre anticuerpos monoclonales
Documento de Investigación 192, 30 de enero de 2024

Por Juan Correa, Catalina de la Puente, Ramiro Picasso y Constanza Silvestrini
TRIPS Waiver Decision for Equitable Access to Medical Countermeasures in the Pandemic: COVID-19 Diagnostics and Therapeutics
Research Paper 191, 25 January 2024

By Nirmalya Syam and Muhammad Zaheer Abbas, PhD
Implementing the Doha Declaration in OAPI Legislation: Do Transition Periods Matter?
Research Paper 190, 24 January 2024

By Patrick Juvet Lowé Gnintedem
The Intersection Between Intellectual Property, Public Health and Access to Climate-Related Technologies
Research Paper 188, 7 December 2023

By Lívia Regina Batista
Patentamiento de anticuerpos monoclonales. El caso de Argentina
Documento de Investigación 186, 14 de noviembre de 2023

Por Juan Correa, Catalina de la Puente, Ramiro Picasso y Constanza Silvestrini

Promoting Jordan’s Use of Compulsory Licensing During the Pandemic
Research Paper 184, 15 September 2023

By Laila Barqawi
Neglected Dimension of the Inventive Step as Applied to Pharmaceutical and Biotechnological Products: The case of Sri Lanka’s patent law
Research Paper 180, 9 August 2023

By Ruwan Fernando
A Response to COVID-19 and Beyond: Expanding African Capacity in Vaccine Production
Research Paper 178, 22 May 2023

By Carlos M. Correa
Where Does Global Health Funding Come From and Where Does It Go?
Research Paper 176, 29 March 2023

By Germán Velásquez

De dónde viene y a dónde va el financiamiento para la salud mundial
Documento de Investigación 176, 29 de marzo de 2023

Por Germán Velásquez
Experiencias internacionales sobre la concesión de licencias obligatorias por razones de salud pública
Documento de Investigación 175, 22 de marzo de 2023

Por Catalina de la Puente, Gastón Palopoli, Constanza Silvestrini, Juan Correa
Leading and Coordinating Global Health: Strengthening the World Health Organization
Research Paper 174, 13 February 2023

By Nirmalya Syam
Analysis of COVID-Related Patents for Antibodies and Vaccines
Research Paper 173, 7 February 2023

By Kausalya Santhanam
Directives pour l’examen des demandes de brevet relatives aux produits pharmaceutiques
Document de Recherche No. 171, 31 janvier 2023

Par Carlos M Correa
Pautas para el Examen de Solicitudes de Patentes Relacionadas con Productos Farmacéuticos
Documento De Investigación 171, 29 De Noviembre De 2022

Por Carlos M Correa
Left on Our Own: COVID-19, TRIPS-Plus Free Trade Agreements, and the Doha Declaration on TRIPS and Public Health
Research Paper 170, 17 November 2022

By Melissa Omino and Joanna Kahumbu
The WTO TRIPS Decision on COVID-19 Vaccines: What is Needed to Implement it?
Research Paper 169, 8 November 2022

By Carlos M. Correa and Nirmalya Syam
TRIPS Flexibilities and Access to Medicines: An Evaluation of Barriers to Employing Compulsory Licenses for Patented Pharmaceuticals at the WTO
Research Paper 168, 28 October 2022

By Anna S.Y. Wong, Clarke B. Cole, Jillian C. Kohler
Lessons From India’s Implementation of Doha Declaration on TRIPS and Public Health
Research Paper 166, 6 October 2022

By Nanditta Batra
Brazilian Competition Law and Access to Health in Brazil: Exploitative Pricing in the Pharmaceutical Sector
Research Paper 143, 11 January 2022

By Bruno Braz de Castro


Reaping the Fruits of Research on Microorganisms: Prospects and Challenges for R&D and Industry in Sri Lanka
Research Paper 159, 15 July 2022

by Ruwan Fernando
Twenty Years After Doha: An Analysis of the Use of the TRIPS Agreement’s Public Health Flexibilities in India
Research Paper 158, 15 June 2022

by Muhammad Zaheer Abbas, PhD
Manufacturing for Export: A TRIPS-Consistent Pro-Competitive Exception
Research Paper 155, 27 May 2022

by Carlos M. Correa and Juan I. Correa
COVID-19 Vaccines as Global Public Goods: between life and profit
Research Paper 154, 9 May 2022

By Katiuska King Mantilla and César Carranza Barona
Patent Analysis for Medicines and Biotherapeutics in Trials to Treat COVID-19
Research Paper 153, 26 April 2022

By Srividya Ravi
An Examination of Selected Public Health Exceptions in Asian Patent Laws
Research Paper 152, 21 April 2022

By Kiyoshi Adachi
¿Podrán las negociaciones en la organización mundial de la salud resultar en un marco justo para la prevención, la preparación y la respuesta ante pandemias como bienes públicos globales?
Documento de investigación No. 147, 28 de febrero de 2022

Viviana Muñoz Tellez
Les négociations au sein de l’Organisation mondiale de la santé peuvent-elles aboutir à un cadre juste pour la prévention, la préparation et la riposte aux pandémies en tant que bien public mondial?

 Document de Recherche 147, 28 février 2022

Viviana Muñoz Tellez
Can Negotiations at the World Health Organization Lead to a Just Framework for the Prevention, Preparedness and Response to Pandemics as Global Public Goods?
Research Paper 147, 28 February 2022

Viviana Muñoz Tellez
A Review of WTO Disputes on TRIPS: Implications for Use of Flexibilities for Public Health
Research Paper 146, 16 February 2022

Nirmalya Syam
The Right to Health in Pharmaceutical Patent Disputes
Research Paper 145, 9 February 2022

Emmanuel Kolawole Oke
A TRIPS-COVID Waiver and Overlapping Commitments to Protect Intellectual Property Rights Under International IP and Investment Agreements
Research Paper 144, 27 January 2022

Henning Grosse Ruse-Khan and Federica Paddeu
Direito Brasileiro da Concorrência e Acesso à Saúde no Brasil: Preços Exploratórios no Setor de Medicamentos
Research Paper 143, 11 de janeiro de 2022

Bruno Braz de Castro
Competition Law and Access to Medicines: Lessons from Brazilian Regulation and Practice
Research Paper 142, 4 January 2022

Matheus Z. Falcão, Mariana Gondo and Ana Carolina Navarrete

Utilising Public Health Flexibilities in the Era of COVID-19: An Analysis of Intellectual Property Regulation in the OAPI and MENA Regions
Research Paper 141, November 2021

Yousuf A Vawda and Bonginkosi Shozi
Implementación de una exención de los ADPIC relacionados con tecnologías y productos sanitarios para la COVID-19: Evitar reclamaciones en virtud de acuerdos de libre comercio e inversión
Documento de investigación 135, Noviembre 2021

Carlos M. Correa, Nirmalya Syam y Daniel Uribe
Mise en œuvre d’une dérogation ADPIC pour les technologies et produits de santé pour la COVID-19: prévenir les réclamations dans le cadre des accords de libre-échange et d’investissement
Document de Recherche 135, Novembre 2021

Carlos M. Correa, Nirmalya Syam et Daniel Uribe
Del SIDA al COVID-19: La OMS ante las crisis sanitarias globales
Documento de investigación 140, Noviembre 2021

Germán Velásquez
Canada’s Political Choices Restrain Vaccine Equity: The Bolivia-Biolyse Case
Research Paper 136, September 2021

Muhammad Zaheer Abbas, PhD
Implementation of a TRIPS Waiver for Health Technologies and Products for COVID-19: Preventing Claims Under Free Trade and Investment Agreements
Research Paper 135, September 2021

Carlos M. Correa, Nirmalya Syam and Daniel Uribe
Restructuring the Global Vaccine Industry
Research Paper 134, September 2021

Felix Lobo
Repensando la fabricación mundial y local de productos médicos tras el COVID-19
Documento de investigación 118, Junio 2021

Germán Velásquez
Interpreting the Flexibilities Under the TRIPS Agreement
Research Paper 132, June 2021

Carlos M. Correa
The TRIPS waiver proposal: an urgent measure to expand access to the COVID-19 vaccines
Research Paper 129, March 2021

Henrique Zeferino de Menezes
Reconsidérations sur la fabrication mondiale et locale de produits médicaux après le COVID-19
Document de Recherche 118, Janvier 2021

Germán Velásquez
Les réformes de l’Organisation mondiale de la Santé a l’époque de COVID-19
Document de Recherche 121, Janvier 2021

Germán Velásquez
Guía para la concesión de licencias obligatorias y uso gubernamental de patentes farmacéuticas
Documento de Investigación 107, Diciembre 2020

Dr. Carlos Correa
Designing Pro-Health Competition
Policies in Developing Countries
Research Paper 125, December 2020

Vitor Henrique Pinto Ido
Las reformas de la Organización Mundial de la Salud en la época de COVID-19
Documento de investigación 121, Noviembre 2020

Germán Velásquez
Practical Implications of ‘Vaccine Nationalism’: A Short-Sighted and Risky Approach in Response to COVID-19
Research Paper 124, November 2020

Muhammad Zaheer Abbas, PhD
The World Health Organization Reforms in the Time of COVID-19
Research Paper 121, November 2020

Germán Velásquez
Patent Analysis for Medicines and Biotherapeutics in Trials to Treat COVID-19
Research Paper 120, October 2020

Srividya Ravi
Re-thinking Global and Local Manufacturing of Medical Products After COVID-19
Research Paper 118, September 2020

Dr. Germán Velásquez
The TRIPS Agreement Article 73 Security Exceptions and the COVID-19 Pandemic
Research Paper 116, August 2020

Frederick Abbott
Equitable Access to COVID-19 Related Health Technologies: A Global Priority
Research Paper 114, June 2020

Dr. Zeleke Temesgen Boru
Guide for the Granting of Compulsory Licenses and Government Use of Pharmaceutical Patents
Research Paper 107, April 2020

Dr. Carlos M. Correa
Eighteen Years After Doha: An Analysis of the Use of Public Health TRIPS Flexibilities in Africa
Research Paper 103, February 2020

Yousuf A Vawda and Bonginkosi Shozi

Second Medical Use Patents – Legal Treatment and Public Health Issues
Research Paper 101, December 2019

Clara Ducimetière
Medicines and Intellectual Property: 10 Years of the WHO Global Strategy
Research Paper 100, December 2019

Dr. Germán Velásquez
Antivirales de acción directa para la Hepatitis C: evolución de los criterios de patentabilidad y su impacto en la salud pública en Colombia
Documento de Investigación 96, Agosto de 2019

Francisco A. Rossi B. y Claudia M. Vargas P.
Access to Medicines: Experiences with Compulsory Licenses and Government Use – The case of Hepatitis C
Research Paper 85, April 2019

Carlos M. Correa and Germán Velásquez
Compulsory Licensing Jurisprudence in South Africa: Do We Have Our Priorities Right?
Research Paper 90, December 2018

Yousuf A Vawda
Acceso a medicamentos: experiencias con licencias obligatorias y uso gubernamental – el caso de la Hepatitis C
Documento de Investigación 85, Mayo 2018

Germán Velásquez
The International Debate on Generic Medicines of Biological Origin
Research Paper 82, November 2017

Germán Velásquez
Intellectual Property in the Trans-Pacific Partnership: Increasing the Barriers for the Access to Affordable Medicines
Research Paper 62R, July 2017

Carlos M. Correa
Intellectual Property, Public Health and Access to Medicines in International Organizations
Research Paper 78, July 2017

Germán Velásquez
Hepatitis C Treatment: A Global Problem
Research Paper 77, May 2017

Germán Velásquez
Mitigating the Regulatory Constraints Imposed by Intellectual Property Rules under Free Trade Agreements
Research Paper 74, February 2017

Carlos M. Correa
The Bolar Exception: Legislative Models and Drafting Options
Research Paper 66, March 2016

Carlos M. Correa
Implementing Pro-Competitive Criteria for the Examination of Pharmaceutical Patents
Research Paper 64, February 2016

Carlos M. Correa
Guidelines on Patentability and Access to Medicines
Research Paper 61, March 2015

Germán Velásquez
Transition Period for TRIPS Implementation for LDCs: Implications for Local Production of Medicines in the East African Community
Research Paper 59, December 2014

Nirmalya Syam
Patent Examination and Legal Fictions: How Rights are Created on Feet of Clay
Research Paper 58, December 2014

Carlos M. Correa
The African Regional Intellectual Property Organization (ARIPO) Protocol on Patents: Implications for Access to Medicines
Research Paper 56, November 2014

Sangeeta Shashikant
Access to Medicines and Intellectual Property: The Contribution of the World Health Organization
Research Paper 47, May 2013

Germán Velásquez
Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing
Research Paper 41, September 2011

Carlos M. Correa
The Right to Health and Medicines: The Case of Recent Negotiations on the Global Strategy in Public Health, Innovation and Intellectual Property
Research Paper 35, January 2011

Germán Velásquez